Vivos Therapeutics Received Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
On September 18, 2024, Vivos Therapeutics, Inc., a premier medical device and technology firm focused on innovative treatments for sleep-related breathing disorders (SRBDs), including obstructive sleep apnea (OSA), announced a significant milestone. The company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary oral medical device, specifically designed to treat moderate to severe OSA and snoring in children. This groundbreaking clearance underscores Vivos' commitment to advancing solutions in the ...